Results of the largest and most comprehensive independent drug trial ever conducted to investigate therapies for schizophrenia suggest that five atypical antipsychotic medications are no more effective — and no safer — than an older, cheaper, drug that has largely been discontinued. The 18-month, $44 million study involved 1400 people and was funded by the US National Institute for Mental Health.
Many second-generation antidepressants, despite differences in drug classification and cost, offer patients essentially the same benefits with little variation in risks, researchers have found. Comparative evidence on anti-depressant drugs indicates only minimal differences in efficacy, although some come with an increased risk of certain side effects.
Materials provided to participants in a new study on the genetic basis of depression prompt some reflection on demonstrating respect for those participating in a research project, empathizing with their perspective and explaining clearly any rationale for denying them feedback on the data (genetic or otherwise) which they have helped create.
New research sheds further light on the role of brain chemistry in anorexia nervosa, indicating that disturbances in the way the brain uses serotonin may persist long after recovery from one type of anorexia.
New research suggests that depression may hasten the progression of heart disease by increasing the levels of a key protein that causes inflammation. In a study of 32 people with heart failure, the 14 patients who felt the most depressed had nearly twice the levels of this protein in their blood.
We comply with the HONcode standard for trustworthy health information: verify here.
